JP2018504436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504436A5 JP2018504436A5 JP2017541301A JP2017541301A JP2018504436A5 JP 2018504436 A5 JP2018504436 A5 JP 2018504436A5 JP 2017541301 A JP2017541301 A JP 2017541301A JP 2017541301 A JP2017541301 A JP 2017541301A JP 2018504436 A5 JP2018504436 A5 JP 2018504436A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- item
- teriflunomide
- tacrolimus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 89
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 16
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 15
- 229960000681 leflunomide Drugs 0.000 claims description 15
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 15
- 229960001967 tacrolimus Drugs 0.000 claims description 15
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 15
- 229960000331 teriflunomide Drugs 0.000 claims description 15
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 15
- 229960003073 pirfenidone Drugs 0.000 claims description 14
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical group C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 14
- 229960000830 captopril Drugs 0.000 claims description 13
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 13
- 229960001195 imidapril Drugs 0.000 claims description 9
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 9
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 8
- 229960005187 telmisartan Drugs 0.000 claims description 8
- -1 tradolapril Chemical compound 0.000 claims description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- 108010061435 Enalapril Proteins 0.000 claims description 6
- 239000005475 Fimasartan Substances 0.000 claims description 6
- 108010007859 Lisinopril Proteins 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 6
- 229960004669 basiliximab Drugs 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- 229930182912 cyclosporin Natural products 0.000 claims description 6
- 229960000873 enalapril Drugs 0.000 claims description 6
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 6
- 229960003489 fimasartan Drugs 0.000 claims description 6
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002394 lisinopril Drugs 0.000 claims description 6
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 229960002582 perindopril Drugs 0.000 claims description 6
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 6
- 229960005330 pimecrolimus Drugs 0.000 claims description 6
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 6
- 229960001455 quinapril Drugs 0.000 claims description 6
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 6
- 229960002769 zofenopril Drugs 0.000 claims description 6
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims description 6
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 5
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 5
- 229930105110 Cyclosporin A Natural products 0.000 claims description 5
- 239000005480 Olmesartan Substances 0.000 claims description 5
- 229960004530 benazepril Drugs 0.000 claims description 5
- 229960002923 denileukin diftitox Drugs 0.000 claims description 5
- 108010017271 denileukin diftitox Proteins 0.000 claims description 5
- 229960002198 irbesartan Drugs 0.000 claims description 5
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 5
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 5
- 229960005117 olmesartan Drugs 0.000 claims description 5
- 229960003401 ramipril Drugs 0.000 claims description 5
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 229960005025 cilazapril Drugs 0.000 claims description 3
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 239000004922 lacquer Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
- 206010025282 Lymphoedema Diseases 0.000 claims description 2
- 229960000932 candesartan Drugs 0.000 claims description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000002502 lymphedema Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical group C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020042965A JP6926263B2 (ja) | 2015-02-05 | 2020-03-12 | 浮腫の治療のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112273P | 2015-02-05 | 2015-02-05 | |
| US62/112,273 | 2015-02-05 | ||
| PCT/US2016/016680 WO2016127013A1 (en) | 2015-02-05 | 2016-02-05 | Compositions and methods for treatment of edema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042965A Division JP6926263B2 (ja) | 2015-02-05 | 2020-03-12 | 浮腫の治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504436A JP2018504436A (ja) | 2018-02-15 |
| JP2018504436A5 true JP2018504436A5 (enExample) | 2019-05-30 |
| JP6704403B2 JP6704403B2 (ja) | 2020-06-03 |
Family
ID=56564721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541301A Expired - Fee Related JP6704403B2 (ja) | 2015-02-05 | 2016-02-05 | 浮腫の治療のための組成物及び方法 |
| JP2020042965A Expired - Fee Related JP6926263B2 (ja) | 2015-02-05 | 2020-03-12 | 浮腫の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042965A Expired - Fee Related JP6926263B2 (ja) | 2015-02-05 | 2020-03-12 | 浮腫の治療のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10251871B2 (enExample) |
| EP (1) | EP3253211B1 (enExample) |
| JP (2) | JP6704403B2 (enExample) |
| CN (2) | CN114588154A (enExample) |
| AU (2) | AU2016215173B2 (enExample) |
| ES (1) | ES3040783T3 (enExample) |
| HK (1) | HK1247789A1 (enExample) |
| WO (1) | WO2016127013A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251871B2 (en) * | 2015-02-05 | 2019-04-09 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
| US10548858B2 (en) * | 2016-08-18 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema |
| IL319182A (en) * | 2018-09-14 | 2025-04-01 | Puretech Lyt 100 Inc | Deuterium-enriched pirfenidone and methods of using it |
| US20250114341A1 (en) | 2018-09-14 | 2025-04-10 | Puretech Lyt 100, Inc. | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
| BR112021008677A2 (pt) * | 2018-11-05 | 2021-08-10 | Apramitha Innovations Private Limited | composições farmacêuticas tópicas de teriflunomida, processo de preparação e uso |
| EP4121049A4 (en) * | 2020-03-18 | 2024-04-03 | Puretech Lyt 100, Inc. | Methods of treating lymphedema with deupirfenidone |
| CN112642065B (zh) * | 2020-12-28 | 2022-08-02 | 锐可医疗科技(上海)有限公司 | 激光治疗仪及存储介质 |
| WO2024059336A1 (en) * | 2022-09-18 | 2024-03-21 | Memorial Sloan Kettering Cancer Center | Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050158371A1 (en) | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
| WO2005011669A1 (ja) * | 2003-08-05 | 2005-02-10 | Dainippon Sumitomo Pharma Co., Ltd. | 経皮投与用医薬組成物 |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| EP1998788A4 (en) * | 2006-03-01 | 2011-08-03 | Ruey J Yu | COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR |
| AU2007230964B2 (en) * | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| CN101484167B (zh) * | 2006-06-15 | 2012-07-04 | 上海睿星基因技术有限公司 | 吡啶酮类衍生物预防和治疗放射性肺损伤的用途 |
| US8454945B2 (en) * | 2007-03-22 | 2013-06-04 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
| US20110288134A1 (en) * | 2008-10-29 | 2011-11-24 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| AR075239A1 (es) * | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
| DE102010015143A1 (de) * | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
| US10251871B2 (en) * | 2015-02-05 | 2019-04-09 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
| US10292961B2 (en) * | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Disulfur bridge linkers for conjugation of a cell-binding molecule |
-
2016
- 2016-02-05 US US15/549,156 patent/US10251871B2/en active Active
- 2016-02-05 AU AU2016215173A patent/AU2016215173B2/en active Active
- 2016-02-05 CN CN202210078205.6A patent/CN114588154A/zh active Pending
- 2016-02-05 EP EP16747309.9A patent/EP3253211B1/en active Active
- 2016-02-05 WO PCT/US2016/016680 patent/WO2016127013A1/en not_active Ceased
- 2016-02-05 ES ES16747309T patent/ES3040783T3/es active Active
- 2016-02-05 HK HK18107279.7A patent/HK1247789A1/zh unknown
- 2016-02-05 CN CN201680016894.0A patent/CN107427007B/zh not_active Expired - Fee Related
- 2016-02-05 JP JP2017541301A patent/JP6704403B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-15 US US16/277,942 patent/US10874651B2/en active Active
-
2020
- 2020-02-18 AU AU2020201161A patent/AU2020201161B2/en active Active
- 2020-03-12 JP JP2020042965A patent/JP6926263B2/ja not_active Expired - Fee Related
- 2020-11-17 US US16/950,652 patent/US11583523B2/en active Active
-
2023
- 2023-01-27 US US18/102,437 patent/US12144805B2/en active Active
-
2024
- 2024-10-12 US US18/914,163 patent/US20250235436A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009039397A3 (en) | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| EA201490875A1 (ru) | Производное аминоалкилзамещенного n-тиенилбензамида | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2016540738A5 (enExample) | ||
| WO2010068810A3 (en) | Certain substituted amides, method of making, and method of use thereof | |
| JP2014516942A5 (enExample) | ||
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016532722A5 (enExample) | ||
| WO2009044392A3 (en) | Novel sirna structures | |
| MX381230B (es) | Novedoso compuesto de 1,2,4-triazina disustituida. | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| WO2017001926A8 (en) | Therapeutic inhibitory compounds | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| JP2010536842A5 (enExample) | ||
| WO2014186623A3 (en) | Methods and compositions for the treatment of a chagas disease | |
| JP2013506684A5 (enExample) | ||
| JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
| DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
| JP2014526541A5 (enExample) | ||
| EP2572721A4 (en) | Pharmaceutical composition including an hif-2 inhibitor as an active ingredient for preventing or treating arthritis | |
| WO2015126930A3 (en) | Booster drug therapy for mycobacterium infections |